Empowering Cannabis Businesses With Data-Driven Strategy and Clear, Actionable Guidance

What We Do

Strake Advisors works with shareholders, boards and management teams of operating businesses in medical cannabis where licensing, cross-border supply chain and capital structure materially shape commercial outcomes.

Engagements span the strategic horizon, not a single transaction event.

Strategy and operations. Strategic planning, organisational design, P&L turnaround, post-merger integration, and operating leadership of regulated production and supply-chain businesses, including interim executive assignments.

Regulatory and licensing. EU-GMP (Part I and Part II) and DEL roadmaps, audit-cycle planning, site readiness, and engagement with Health Canada, the MHRA, BfArM and related authorities. Licence-transfer assessments in change-of-control scenarios.

Export, import and cross-border trade. Architecture of multi-jurisdictional supply chains, including narcotics-licensed flows between Canada, the European Union, the United Kingdom and Australia.

Growth strategy. Buy-versus-build analysis, market entry, channel and partnership structuring, and the design of commercial engines that scale organically — not solely through transactions.

M&A and capital advisory. Sell-side and buy-side processes, deal structuring, NDA-controlled bilateral engagements, capital advisory, and shareholder-side support through diligence, negotiation, signing and integration.

Engagements span Europe, Canada, the United States and Australia. Every assignment is senior-led from origination through close; there is no associate-staffing model.

Founder Profile

Strake Advisors was founded by Todd Steinberg, who brings over 35 years of senior leadership across cannabis and global capital markets.

Since 2011, Todd has worked principally in the international cannabis sector — as an operator, board member, investor and adviser — across the full value chain from genetics and cultivation through extraction, manufacturing, export and capital.

Most recently he served as Interim Company Head of an EU-GMP and DEL-licensed Canadian cultivation and manufacturing platform, where he delivered the business's first cash-flow- and EBITDA-positive quarter and completed the post-merger integration of Canadian operations into a UK parent.

He has advised a multi-national operator on European expansion across Germany, the UK, France and Poland; acted as deal advisor on a $50 million+ European medical cannabis supply-chain merger; and positioned and sold a cannabis genetics business to a publicly-traded industry leader. He has done business in over 25 countries and holds Health Canada security clearance.

Prior to cannabis, Todd held senior management positions across leading global investment banks.

As Global Head of Derivatives, Finance & Proprietary Trading at Macquarie Securities, he led a 275-person division across ten international offices. At BNP Paribas Americas, as Head of Equities & Commodity Derivatives, he tripled the franchise to $800 million in revenue and was lead negotiator on the $300 million acquisition of Bank of America's Prime Brokerage business. He held earlier senior leadership roles at Wachovia Securities, UBS and Bear Stearns.

Todd holds an MBA in Finance and International Business from NYU Stern School of Business and a BS in Finance and Accounting from the University of Colorado.